drugset / Trial / NCT01068704
Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if BMS-690514 + letrozole will be more effective than lapatinib + letrozole in patients who have metastatic hormone receptor positive breast cancer after developing progressive disease immediately following adjuvant antiendocrine therapy
Timeline
- Start
- 2010-06
- Primary completion
- 2010-12
- Completion
- 2010-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | BMS-690514 | Small molecule | 200 mg | Oral |
| Comparator | Lapatinib | Small molecule | 1500 mg | Oral |
| Comparator | Letrozole | Other / unclassified | 2.5 mg | Oral |